Bisphosphonates or denosumab discontinuation and risk of fractures

Affiliations

¹ Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece. Electronic address: anastath@endo.gr.
² Laboratory of Clinical and Molecular Endocrinology, 1st Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
³ Department of Endocrinology, Diabetes and Metabolism, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.

Comment

Athanasios D Anastasilakis et al. Maturitas. 2017 Aug.

. 2017 Aug:102:75.

doi: 10.1016/j.maturitas.2017.04.016. Epub 2017 Apr 27.

¹ Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece. Electronic address: anastath@endo.gr.
² Laboratory of Clinical and Molecular Endocrinology, 1st Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
³ Department of Endocrinology, Diabetes and Metabolism, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.

No abstract available

Comment in

Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.
Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollieres FA, Goulis DG. Anagnostis P, et al. Maturitas. 2017 Aug;102:76-77. doi: 10.1016/j.maturitas.2017.04.019. Epub 2017 Apr 28. Maturitas. 2017. PMID: 28483346 No abstract available.

Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollieres FA, Goulis DG. Anagnostis P, et al. Maturitas. 2017 Jul;101:23-30. doi: 10.1016/j.maturitas.2017.04.008. Epub 2017 Apr 15. Maturitas. 2017. PMID: 28539165